Cancer
Conditions
Keywords
cancer, immunotherapy, checkpoint inhibitors, immune-related adverse events
Brief summary
Study of ApricityRx™ for Management of IR-AEs for patients on I-O therapy. Patients currently receiving immunotherapy will be asked to consent to participate in ApricityRx software platform mobile telephone application to report symptoms, view educational content in video form about IO and irAEs and communicate with site study team.
Interventions
OTHERApricityRx mobile application
AE detection and monitoring software
Sponsors
Apricity Health, Inc
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Inclusion criteria
* Confirmed cancer diagnosis * Prescribed treatment with immune-checkpoint inhibitor * Age ≥ 18 years * Ability to understand and the willingness to sign a written informed consent document.
Exclusion criteria
* Uncomfortable with or unwilling to use digital or mobile technology * Lack of a smart phone with compatible operating systems: iOS version 10 and above, or Android 6.0 Marshmallow * Presence of any medical, psychological or social condition that, in the opinion of the investigator, would preclude participation in this study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Evaluate digital therapeutic mobile app to capture and transmit to care team patient-generated health data and access education content on IO and irAEs | 12 weeks | Number of times and percentage of study participants who use the app to report patient reported health data during a 12 week period and access education videos. |
Countries
United States
Contacts
Primary ContactResearch Nurse Navigator
Outcome results
None listed